Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 3963-3970

  Sharma, Sunil ^a   Kemeny, Nancy ^a   Schwartz, Gary K ^a   Kelsen, David ^a   O’Reilly, Eileen ^a   Ilson, David ^a   Kleban, Sarah ^a   Hollywood, Ellen ^a   Saltz, Leonard B ^a   Ducharme, Martin P ^b   Coyle, John ^c   De Jager, Robert L ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MDS Inc   (Canada)

^c Daiichi Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; EXATECAN;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPARTMENT MODEL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; LIVER CARCINOMA; MALE; NAUSEA; NEUTROPENIA; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CARCINOMA; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 0035678052     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. The current status of camptothecin analogues as antitumor agents
2. Antitumor activities of camptothecin analogues against human esophageal cancer
3. High potency of a camptothecin derivative DX-8951 might be attributed to good membrane permeability
4. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo
5. Activity of DX-8951f, a water soluble camptothecin derivative, on primary human tumor colony-forming units
6. Antitumor activity of topoisomerase I inhibitors against a pediatric solid tumor panel
7. Antitumor effect of DX-8951f, a new camptothecin derivative in various murine models
8. Remarkable synergistic interaction between camptothecin analogs and cisplatin against human esophageal cancer cell lines
9. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11 resistant variants cultured in vitro and xenografted into nude mice
10. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin-derivative, against various human tumors xenografted into nude mice
11. A program package for simulation and parameter estimation in pharmacokinetic systems
12. DNA topoisomerases
13. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
14. Expression and relationship between topoisomerase I and II α genes in tumor and normal tissues in esophageal, gastric and colon cancers
15. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer
16. P-Glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy
17. Topoisomerase I and II levels in human lymphoma cell lines SU-4 and SU-4R
18. DNA topoisomerase poisons as antitumor drugs
19. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase 1
20. Topoisomerase I inhibitors: Review and update
21. Phase I and pharmacokinetic study of DX-8951f, a novel topoisomerase inhibitor
22. Dose-schedule optimization of the hexacyclic camptothecin (CPT) analog DX-8951f: A Phase I and pharmacokinetic study with escalation of both treatment duration and dose
23. Phase I and pharmacokinetic (PK) study of DX-8951f, a novel camptothecin analog, given as 30 minute infusion daily for 5 days
24. Phase I and clinical pharmacology of DX-8951f, a new camptothecin derivative, infused over 30 minutes every 3 weeks
25. DX-8951f: Phase I and pharmacokinetic study of a novel camptothecin analogue administered by 24-hour continuous infusion to patients with advanced solid tumors
26. DX-8951f: Summary of Phase I clinical trials
27. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during Phase I trials
28. Phase I and pharmacokinetic trial of weekly CPT-11
29. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer